Lexiva

Lexiva is a brand name of fosamprenavir, approved by the FDA in the following formulation(s):

LEXIVA (fosamprenavir calcium - suspension; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: June 14, 2007
  
  Strength(s): EQ 50MG BASE/ML ^[RLD]

LEXIVA (fosamprenavir calcium - tablet; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: October 20, 2003
  
  Strength(s): EQ 700MG BASE ^[RLD]

Has a generic version of Lexiva been approved?

No. There is currently no therapeutically equivalent version of Lexiva available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lexiva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Prodrugs of aspartyl protease inhibitors
  Patent 6,436,989
  Issued: August 20, 2002
  Inventor(s): Michael R.; Hale & Roger D.; Tung & Christopher T.; Baker & Andrew; Spaltenstein
  Assignee(s): Vertex Pharmaceuticals, Incorporated
  The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.
  
  Patent expiration dates:
  
  
  • December 24, 2017
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 24, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
  Patent 6,514,953
  Issued: February 4, 2003
  Inventor(s): Ian Gordon; Armitage & Andrew David; Searle & Hardev; Singh
  Assignee(s): SmithKline Beecham Corporation
  The invention relates to calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate, to processes for its preparation, and to its use in the treatment of diseases caused by retroviruses.
  
  Patent expiration dates:
  
  
  • July 15, 2019
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • January 15, 2020
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Lexiva Consumer Information (Drugs.com)
• Lexiva Consumer Information (Wolters Kluwer)
• Lexiva Suspension Consumer Information (Wolters Kluwer)
• Lexiva Consumer Information (Cerner Multum)
• Lexiva Advanced Consumer Information (Micromedex)
• Lexiva AHFS DI Monographs (ASHP)
• Fosamprenavir Consumer Information (Wolters Kluwer)
• Fosamprenavir Suspension Consumer Information (Wolters Kluwer)
• Fosamprenavir Consumer Information (Cerner Multum)
• Fosamprenavir Advanced Consumer Information (Micromedex)
• Fosamprenavir Calcium AHFS DI Monographs (ASHP)